Program

Download PDF of Program here.

Sunday, July 22, 2012

Registration Check-In

11:00 a.m. - 1:15 p.m., Rotunda, Main Floor

Coffee & Tea Welcome Reception, 

12:00 - 1:15 p.m., Ground Floor Lobby, outside of Boardroom

Opening Remarks

1:15 - 4:30 p.m., Boardroom, Ground Floor

CAR / PXR
Oral Presentations I

1:30 - 2:00 p.m.
Structural Biology of Xenobiotics Receptor CAR
and Other Nuclear Receptors
H. Eric Xu, VARI/SIMM Research Center

2:00 - 2:30 p.m.
In Vitro Identification of Novel CAR Activators:
Integration of Computational and Biological Approaches
Hongbing Wang, University of Maryland

2:30-3:00 p.m.
Natural Splice Variation in Human CAR Specifies Receptors
With Unique Biological Properties
Curt Omiecinski, Penn State University

3:00 - 3:30 p.m.
Regulation of Drug Transporters by Nuclear Receptors in the Brain
Reina Bendayan, University of Toronto

3:30 - 4:00 p.m.
Role of PXR in Malignancy
Sridhar Mani, Albert Einstein College of Medicine

4:00 - 4:30 p.m
The Endobiotic Function of CAR and PXR in Energy Metabolism
Wen Xie, University of Pittsburgh

Reception

4:30 - 6:00 p.m., Patio, Main Floor

Dinner

6:00 - 7:30 p.m., Ballroom, Main Floor

Plenary Address

7:30 - 8:30 p.m., Boardroom, Ground Floor

Transcription Dynamics, Chromatin Transitions,
and the Mechanism of Regulatory Element Function
Gordon Hager, National Cancer Institute, NIH

Monday, July 23, 2012

Keynote Address

8:00 - 9:00 a.m., Boardroom, Ground Floor

Incorporating Our Evolving Understanding of Nuclear Receptor Action
Into Mechanism-Based Screens for Endocrine Disrupters
Donald P. McDonnell, Duke University Medical School

PPAR
Oral Presentations II

9:15 - 10:45 a.m., Boardroom, Ground Floor

9:15 - 9:45 a.m.
Genome-Wide Approaches to Understanding Nuclear Receptor Function
Christopher K. Glass, University of California, San Diego

9:45 - 10:15 a.m.
Role of PPARa in Chemical Toxicity and Carcinogenesis
Frank Gonzalez, National Cancer Institute, NIH

10:15 - 10:45 a.m.
Mechanism of Action of Novel Insulin Sensitizers
Patrick R. Griffin, The Scripps Research Institute

Poster Exhibits / Refreshments

10:45 a.m. - 12:00 p.m., Faculty / Staff Club, Ground Floor

Luncheon / Free Time

12:00 - 1:30 p.m.

PPAR
Oral Presentations III

1:30 - 3:00 p.m., Boardroom, Ground Floor

1:30 - 2:00 p.m.
PPARβ/δ, A Modulator of Cytokine Signaling and Tumorigenesis
Rolf Müller, Philipps University, Germany

2:00 - 2:30 p.m.
Peroxisome Proliferator-Activated Receptor-β/δ-Dependent Regulation of Cancer
Jeff Peters, Penn State University

2:30 - 3:00 p.m.

Coffee / Tea Refreshments

3:00 - 3:30 p.m., Ground Floor Lobby outside of Boardroom

Ah Receptor, Oral Presentations IV

3:30 - 5:00 p.m., Boardroom, Ground Floor

3:30 - 4:00 p.m.
Development and Therapeutic Potential of Selective Ah Receptor Modulators
Gary H. Perdew, Penn State University

4:00 - 4:30 p.m.
Control of Human Hematopoietic Stem Cell Self-Renewal and
Differentiation by the Aryl Hydrocarbon Receptor
Michael P. Cooke, Genomics Institute of the Novartis Research Foundation

4:30 - 5:00 p.m.
AhR and the Immune Cells of Barrier Organs
Charlotte Esser, Institut für Umweltmedizinische Forschunt (IUF), Germany

Reception

5:30 - 7:00 p.m., The Arboretum at Penn State Pavilion

Dinner

7:00 - 8:30 p.m., Patio

Tuesday, July 24, 2012

Ah Receptor, Oral Presentations V

8:00 - 9:30 a.m., Boardroom, Ground Floor

8:00 - 8:30 a.m.
Biological Properties of the High Affinity Endogenous Aryl
Hydrocarbon Receptor Ligand FICZ
Agneta Rannug, Karolinska Institute, Sweden

8:30 - 9:00 a.m.
Dioxin, Clocks and Oxygen
Christopher Bradfield, University of Wisconsin

9:00 - 9:30 a.m.
The Aryl Hydrocarbon Receptor as a Drug Target
for Treating Advanced Breast Cancer
Stephen Safe, Texas A & M University

Poster Exhibits / Refreshments

9:30 - 10:30 a.m., Faculty / Staff Club, Ground Floor

Applications / Biological Utility of Receptor Technologies,
Oral Presentations VI

10:30 a.m. - 1:00 p.m., Boardroom, Ground Floor

10:30 - 11:00 a.m.
Early Safety Assessment - When Chemistry Meets Biology
Craig E. Thomas, Eli Lilly and Company

11:00 - 11:30 a.m.
Nuclear Receptor Activity Across Chemical Classes:
Comparing ER and AhR Activity Trends Between Environmental Chemicals
and Pharmaceuticals and Reference Compounds
Richard Judson, National Center for Computational Toxicology

11:30 a.m. - 12:00 p.m.
The AH Receptor: Species Studies, Mode-of-Action,
and Implication for Human Risk Assessment
J. Craig Rowlands, The Dow Chemical Company

12:00 - 12:30 p.m.
Cryopreserved HepaRG Cells™ as Alternatives to Primary
Human Hepatocytes for Modeling Receptor Activation Phenotypes
Stephen Ferguson, Life Technologies, Inc.

12:30 - 1:00 p.m.
Nuclear Receptors as Nutritional Targets:
Implications for Prevention and Treatment of Metabolic Syndrome
Jack Vanden Heuvel, Penn State University

Summary Remarks

1:00 - 1:30 p.m., Boardroom, Ground Floor

Meeting Adjourned

1:30 p.m.

Updated 5/10/2012